Get the Stockscreener App
1.755
1.68%
-0.035
Heron Therapeutics Inc stock is traded at $1.755, with a volume of 949.72K.
It is down -1.68% in the last 24 hours and up +4.14% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.79
Open:
$1.79
24h Volume:
949.72K
Relative Volume:
0.33
Market Cap:
$269.21M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-10.97
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
+3.53%
1M Performance:
+4.14%
6M Performance:
-12.00%
1Y Performance:
-22.12%
1-Day Range:
$1.72
$1.80
1-Week Range:
$1.66
$1.9099
52-Week Range:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.755 | 269.21M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.10 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
712.14 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.00 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.79 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Heron Therapeutics (NASDAQ:HRTX) Share Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
An analyst sees good growth prospects for Heron Therapeutics Inc (HRTX) - SETE News
Financial Metrics Check: Heron Therapeutics Inc (HRTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Are Heron Therapeutics Inc (HRTX) shares a good deal now? - US Post News
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - MarketBeat
JPMorgan Chase & Co. Has $411,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by StockNews.com - Defense World
HRTX’s Market Whiplash: 15.03% YTD Rise, 15.03% Rise in 30 Days - The InvestChronicle
Great week for Heron Therapeutics, Inc. (NASDAQ:HRTX) institutional investors after losing 26% over the previous year - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a favorite amongst institutional investors who own 58% - Yahoo Finance
Heron Therapeutics (NASDAQ:HRTX) Upgraded by StockNews.com to Buy Rating - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Buy at StockNews.com - Defense World
Barclays PLC Purchases 50,109 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Congress Park Capital LLC Grows Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to Hold - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
San Diego Biotech Firm Heron Therapeutics Shifts Operations to North Carolina - MSN
Principal Financial Group Inc. Raises Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Geode Capital Management LLC Sells 66,974 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Jane Street Group LLC Cuts Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Franklin Resources Inc. Sells 6,304,716 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Franklin Resources Inc. Decreases Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to “Hold” at StockNews.com - Defense World
This San Diego biotech is moving its HQ to North Carolina - The San Diego Union-Tribune
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by State Street Corp - MarketBeat
Heron Therapeutics to Shift Headquarters from San Diego to Cary, - Hoodline
California public company relocates to North Carolina - The Business Journals
Heron Therapeutics Relocates Headquarters to North Carolina - TipRanks
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina - PR Newswire
Heron Therapeutics (NASDAQ:HRTX) Cut to "Hold" at StockNews.com - MarketBeat
Fmr LLC Has $859,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Verition Fund Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stake Lowered by Charles Schwab Investment Management Inc. - Defense World
U.S. District Court Upholds Validity of CINVANTI® Patents - The Eastern Progress Online
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - The Eastern Progress Online
StockNews.com Upgrades Heron Therapeutics (NASDAQ:HRTX) to "Buy" - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.com - Defense World
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - Kilgore News Herald
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - The Eastern Progress Online
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):